Yes, allopurinol can cause diarrhea, and it appears in the product labeling as a reported gastrointestinal adverse reaction. It is usually mild and dose-related rather than a sign of allergy. The more important question is how to tell ordinary loose stools from the rare hypersensitivity reaction that makes allopurinol dangerous. That distinction drives every practical decision below.
Allopurinol lowers uric acid by blocking xanthine oxidase, the enzyme that converts hypoxanthine to xanthine and xanthine to uric acid. The drug is a structural analog of hypoxanthine, so it binds the enzyme's active site and slows the final two steps of purine breakdown. Uric acid production falls, and the precursor compounds upstream of the block rise in blood and urine.
That mechanism explains most of the drug's benefits and most of its risks. It does not, by itself, explain diarrhea. Gut effects likely arise from several overlapping routes: direct mucosal exposure to the drug and its metabolites, shifts in the purine substrate available to gut bacteria, and, in a minority of patients, immune-mediated drug hypersensitivity that can involve the intestinal lining.
One nuance matters for anyone reading a label. The recorded frequency of diarrhea in allopurinol trials is low, typically reported in the range of roughly 1 to 3 percent, and controlled trials often show rates close to placebo. Label lists aggregate decades of spontaneous reports, so a listed reaction is not proof of a common causal link. Absence of a high trial rate is equally not proof of no link. [FDA label for allopurinol]
Mechanism: Why a Purine-Blocker Reaches the Gut
Allopurinol is absorbed rapidly and converted largely to oxypurinol, its long-lived active metabolite. Oxypurinol is cleared almost entirely by the kidney, which is why renal function governs drug exposure. Higher exposure means more drug delivered to the intestinal lumen and more substrate shifted toward other purine pathways.
Gut bacteria participate in purine metabolism. When xanthine oxidase is blocked, hypoxanthine and xanthine accumulate and more purine substrate reaches the colon. Microbial enzymes can convert these compounds into metabolites that draw water into the lumen or irritate the mucosa. This is a plausible, not proven, route to loose stools.
A second route is direct. Drug and metabolite contact with enterocytes can alter local transport and mucosal turnover. Most patients tolerate this without symptoms, which suggests the effect is threshold-dependent rather than universal.
A third route is immune. Allopurinol hypersensitivity syndrome can include gastrointestinal features alongside fever, rash, eosinophilia, and organ injury. Diarrhea in that setting is not a benign side effect. It is part of a systemic reaction that requires immediate drug discontinuation and urgent evaluation. [FDA label for allopurinol]
Plain-language version: the drug changes the chemical pool in your gut, and a few people react to that change with loose stools.
Quantified Context: How Common Is It Really?
The honest answer is that diarrhea is uncommon and hard to attribute in any single patient. Trial data place gastrointestinal complaints among the most frequently reported adverse events, yet diarrhea specifically sits at the low end, often near placebo rates. Spontaneous reporting systems capture events without a control group, so they cannot establish causation.
Dose and kidney function are the variables that matter most. Allopurinol is renally cleared as oxypurinol, so impaired kidney function raises exposure for any given dose. Clinicians adjust starting doses in chronic kidney disease for exactly this reason. Higher exposure plausibly raises the chance of any adverse effect, including gut symptoms.
Timing gives a useful clue. Most benign gut upset emerges within the first days to weeks of therapy and settles as the body adapts. Symptoms that begin weeks to months later, especially with fever or rash, point away from simple intolerance.
A counterintuitive professional caveat: a patient who tolerates allopurinol for years and then develops diarrhea on it is more likely to have an unrelated cause, such as infection, a new medication, or a dietary change, than a delayed drug effect. New symptoms in a long-stable patient should not be reflexively blamed on the drug.
Timeline: What Gut Symptoms Mean Over Time
| Time since starting allopurinol | Typical pattern | What it usually means | Action threshold |
|---|---|---|---|
| Days 1 to 7 | Mild loose stools, no fever, no rash | Common early intolerance | Hydrate, monitor, call clinician if worsening |
| Weeks 1 to 4 | Diarrhea with rash, fever, or facial swelling | Possible hypersensitivity | Stop drug, seek urgent care |
| Weeks 2 to 8 | Persistent diarrhea without systemic signs | Drug intolerance or unrelated cause | Contact prescriber for review |
| Months 1 to 6 | New diarrhea in a stable patient | Usually unrelated cause | Evaluate for infection and other drugs |
| Any time with blood or mucus | Inflammatory or infectious picture | Not typical drug intolerance | Urgent medical evaluation |
Use this table as a reasoning aid, not a diagnosis. The clinically decisive features are fever, rash, mucosal involvement, and organ symptoms, because those separate a benign side effect from a serious reaction.
Edge Cases and Red Flags
Certain patients deserve closer attention. People with chronic kidney disease have higher oxypurinol exposure and a higher baseline risk of adverse drug events. Older adults often take multiple medications, and diarrhea is a common effect of antibiotics, NSAIDs, metformin, and many others, so attribution requires a medication review.
Red-flag warnings: Fever, rash, or facial swelling alongside diarrhea: stop the drug and seek urgent care, because this can signal allopurinol hypersensitivity syndrome. Blood or mucus in stool, or severe abdominal pain: evaluate urgently for infection or colitis. Diarrhea causing dizziness, reduced urination, or confusion: assess for dehydration. Diarrhea beginning with a new antibiotic or another new drug: the other agent may be responsible. Diarrhea in a patient with kidney disease who has had a dose increase: review dosing with the prescriber.
The serious reaction to know is allopurinol hypersensitivity syndrome, which carries substantial mortality when unrecognized. It is rare, and it is not the same thing as loose stools. The presence of rash, fever, or eosinophilia is the dividing line. [FDA label for allopurinol]
Misconceptions and Alternatives
A common misconception is that any gut symptom on allopurinol means the drug must be stopped permanently. Mild, self-limited loose stools often resolve, and stopping a urate-lowering drug has its own costs, including gout flares and lost cardiovascular and renal benefits over time. The decision belongs with the prescriber, guided by severity and timing.
A second misconception is that switching drugs eliminates gut risk. Every urate-lowering option has its own gastrointestinal profile. The table below compares the main alternatives on gut tolerability, not on overall superiority.
| Option | Gut side-effect profile | Key practical notes |
|---|---|---|
| Allopurinol | Diarrhea uncommon, usually early and mild | Renally cleared metabolite; dose adjusted in kidney disease |
| Febuxostat | Diarrhea and nausea reported; generally similar GI burden | No renal dose adjustment needed; cardiovascular cautions apply |
| Probenecid | GI upset possible | Less used; requires adequate kidney function and hydration |
| Pegloticase | Infusion reactions dominate; GI less prominent | Reserved for refractory disease; specialized administration |
| Diet and lifestyle alone | No drug GI effects | Modest urate reduction; often insufficient for gout targets |
Febuxostat is a non-purine xanthine oxidase inhibitor, so it avoids some allopurinol-specific metabolic routes, but it does not eliminate gastrointestinal effects. The American College of Rheumatology conditionally recommends allopurinol as first-line therapy for most patients with gout, with febuxostat as an alternative. Gastrointestinal tolerance is one factor among several in that choice. [American College of Rheumatology guideline]
A practical middle path exists for mild intolerance: taking the drug with food and splitting doses can reduce peak gut exposure in some patients. This is a conversation to have with the prescriber, not a self-directed change.
Practical Actions and Thresholds
If diarrhea starts after beginning allopurinol, work through these steps in order.
Check for red flags first: fever, rash, facial swelling, blood in stool, or severe pain. Any of these means stop the drug and seek urgent care. Note the timing. Symptoms in the first two weeks without systemic signs are more consistent with benign intolerance than with hypersensitivity. Review other new medications, especially antibiotics, NSAIDs, and metformin. Diarrhea is a common effect of each. Maintain hydration and monitor urine output. Seek care if dizziness or reduced urination develops. Contact the prescriber before stopping or changing the drug if symptoms are mild and no red flags are present. Ask about dose review if kidney function has changed or a dose was recently increased.
Thresholds to reconcile: mild symptoms lasting under a few days without systemic signs usually warrant monitoring and a clinician call. Symptoms lasting beyond about a week, or any symptom with fever or rash, warrant prompt review. These are general reasoning thresholds, not dosing instructions, and they do not replace clinical judgment.
One further caveat: do not stop allopurinol abruptly during an active gout flare without discussing it, because urate swings can worsen symptoms. Flare management and urate-lowering therapy are separate decisions.
Limitations of the Evidence
The causal picture is genuinely uncertain. Controlled trial data show low and often placebo-comparable diarrhea rates, while label lists reflect decades of uncontrolled reports. Neither source can prove that allopurinol caused diarrhea in any individual patient.
Mechanistic evidence for a gut-specific pathway is indirect and largely inferred from purine metabolism and bacterial substrate handling rather than from dedicated human studies. No large trial has been designed to isolate allopurinol-attributable diarrhea as a primary endpoint.
The most defensible conclusion is that allopurinol can cause diarrhea, usually mildly and early, while the serious risk to watch for is hypersensitivity with systemic features. The gap between those two statements is where good clinical judgment lives.